- Home
- CMRE vs AUPH Comparison
CMRE vs AUPH Comparison
Compare CMRE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMRE
- AUPH
- Stock Information
- Founded
- CMRE 1974
- AUPH 1993
- Country
- CMRE Monaco
- AUPH Canada
- Employees
- CMRE N/A
- AUPH N/A
- Industry
- CMRE Marine Transportation
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- CMRE Consumer Discretionary
- AUPH Health Care
- Exchange
- CMRE Nasdaq
- AUPH Nasdaq
- Market Cap
- CMRE 1.0B
- AUPH 1.1B
- IPO Year
- CMRE 2010
- AUPH 1999
- Fundamental
- Price
- CMRE $9.59
- AUPH $8.63
- Analyst Decision
- CMRE Hold
- AUPH Strong Buy
- Analyst Count
- CMRE 2
- AUPH 2
- Target Price
- CMRE $13.50
- AUPH $11.50
- AVG Volume (30 Days)
- CMRE 479.1K
- AUPH 2.1M
- Earning Date
- CMRE 07-30-2025
- AUPH 07-31-2025
- Dividend Yield
- CMRE 4.83%
- AUPH N/A
- EPS Growth
- CMRE N/A
- AUPH N/A
- EPS
- CMRE 2.44
- AUPH 0.27
- Revenue
- CMRE $2,054,690,000.00
- AUPH $247,295,000.00
- Revenue This Year
- CMRE N/A
- AUPH $12.15
- Revenue Next Year
- CMRE N/A
- AUPH $18.34
- P/E Ratio
- CMRE $3.92
- AUPH $32.66
- Revenue Growth
- CMRE 18.22
- AUPH 29.20
- 52 Week Low
- CMRE $6.63
- AUPH $5.20
- 52 Week High
- CMRE $15.96
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- CMRE 59.66
- AUPH 54.74
- Support Level
- CMRE $9.14
- AUPH $8.73
- Resistance Level
- CMRE $9.54
- AUPH $9.19
- Average True Range (ATR)
- CMRE 0.27
- AUPH 0.44
- MACD
- CMRE 0.01
- AUPH 0.09
- Stochastic Oscillator
- CMRE 90.14
- AUPH 70.60
About CMRE Costamare Inc. $0.0001 par value
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.